![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 3 of 3. This is the beginning of the thread.
Posted by Anna Laura on April 10, 2002, at 0:54:11
From:
http://www.hivandhepatitis.com/health/110901a.html
Bristol-Myers Squibb Unveils Research Pipeline to Investment CommunityBristol-Myers Squibb Company (BMS), a leading manufacturer of HIV drugs and medications for a wide range of diseases, announced its plans to seek regulatory approval of three major products a year for several years, starting in 2003. The company will seek approval for five compounds over the next 12 months alone.
At a company presentation, BMS executives presented details about some of the more than 50 compounds in the company's early and late-stage research pipeline and provided highlights of a selection of its more than 100 drug discovery programs.
"Our 'Strategy for Growth' plan, which was announced just one year ago, has already delivered significant results," said Peter R. Dolan, BMS chairman and chief executive officer. "During the past year, the company has been quite visible in the area of acquisitions and divestitures.
"The organization has also been aggressively focused on efforts to accelerate and enrich our future pipeline. As a result of these efforts, we believe we have the products that will allow us to achieve our goal of launching threepotential blockbuster products a year for several years starting in 2003 and we are hopeful that the first of these products may launch in 2002."
Within the next year, BMS expects to submit global regulatory filings for the following potential "best-in-class" or "first-in-class" products. Product names highlighted in blue are in development for the treatment of HIV infection or for chronic hepatitis B:
Aripiprazole: a novel and potentially best-in-class compound under investigation for the treatment of schizophrenia and related disorders. Aripiprazole is a next-generation antipsychotic that, in completed trials, has demonstrated efficacy with an excellent safety and tolerability profile and once-daily dosing with no need for titration in Phase III clinical studies. During the meeting, Bristol- Myers Squibb executives announced that the company had submitted the New Drug Application (NDA) for aripiprazole on October 31, 2001. The company also plans to submit for filing the Marketing Authorisation Application (MAA) in Europe by the end of 2001.
CRF antagonists - Corticotropin releasing factor antagonists are being developed as rapid onset of action agents for use in treating depression and possibly, anxiety.
Posted by johnj on April 10, 2002, at 12:38:44
In reply to CRF antagonists to be approved in 2003?, posted by Anna Laura on April 10, 2002, at 0:54:11
I think CRF's are way down the line, and are probably only in phase 1 trials. Go to Neurocrine Bioscience and you can see where CRF's are at. I am more excited about the insomnia drug that they will put our sometime in 2003 assuming phase III trials all go well. take care
John
Posted by paulb on April 11, 2002, at 17:52:01
In reply to CRF antagonists to be approved in 2003?, posted by Anna Laura on April 10, 2002, at 0:54:11
i think CRF antagonists may be beneficial for persons under general stress as well as persons who are unwell as the mechansim is that overzealous cortisal activity is inhibited, a hormone released when when we are stressed. it will be interesting to see the impact some of these news medications have?
paulb
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.